ABBV vs ADBE: Which Is the Better Buy?
Side-by-side comparison of AbbVie Inc. and Adobe Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-04-29.
AbbVie Inc. · Healthcare
$197.69
+6.3% upside to fair value
Grade C
High Quality
VS
Adobe Inc. · Technology
$248.16
+45.0% upside to fair value
High Conviction
Grade B
QuantHub Verdict
ADBE has more upside to fair value
(+45.0%).
ADBE trades at a lower forward P/E
(14.1x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ABBV |
ADBE |
| Current Price |
$197.69 |
$248.16 |
| Fair Value Estimate |
$210.22 |
$359.82 |
| Upside to Fair Value |
+6.3%
|
+45.0%
|
| Market Cap |
$349.7B |
$101.2B |
| Forward P/E |
83.3x
|
14.1x
|
| EV / EBITDA |
23.4x
|
—
|
| Price / Sales |
5.7x
|
4.1x
|
| Price / FCF |
18.7x
|
9.8x
|
| Revenue Growth YoY |
+10.0%
|
+3.3%
|
| Gross Margin |
70.2%
|
89.1%
|
| Operating Margin |
26.7%
|
36.6%
|
| Return on Equity |
-361.6%
|
62.3%
|
| Dividend Yield |
0% |
— |
| FCF Yield |
5.35%
|
10.2%
|
| Analyst Consensus |
Strong Buy
|
Hold
|
Investment Thesis
AbbVie Inc. is a leading healthcare company specializing in drug manufacturing with a strong focus on immunology, neuroscience, oncology, and aesthetics. The company benefits from a durable competitive moat driven by blockbuster drugs such as Skyrizi and Rinvoq, which are experiencing rapid growth and offsetting declines from Humira due to biosimilar competition. Despite a high trailing and forwa…
Adobe Inc. develops industry-leading creative software, digital experience platforms, and publishing tools, powering digital content creation and marketing for professionals worldwide. The business excels with high gross margins above 89%, a sticky subscription model driving recurring revenue over $17B ARR, and dominant moats in digital media, though it faces intensifying AI competition and slowi…
Accumulation Zones
| Metric |
ABBV |
ADBE |
| Zone Low |
$157.66 |
$269.87 |
| Zone High |
$178.69 |
$305.85 |
| In Buy Zone? |
No
|
Yes
|